Entera Bio Q3 2026 Results: Net Loss of $15.6M, Loss Widens
Entera Bio Ltd. is a development-stage biopharmaceutical company focusing on oral peptide delivery, specifically product candidates EB613 for osteoporosis and EB612 for hypoparathyroidism. As of November 2, 2026, the company had 174,137,771 ordinary shares outstanding and continues to operate with a history of losses, relying on potential strategic partnerships and future capital raises to fund its clinical development programs.
- Key figure
- Net loss $15.6M